It's definitely the case that over time in each project there will be a different set of metrics that become important.
In the early part of the R and D program, essentially the metrics relate to whether the R and D is being executed as contracted in the agreement, which is not a stage at which we're seeing benefits other than there's direct employment, there's actual activity, being an activity of procurement, there's knowledge development, and so forth that's occurring at that early stage. That's the one in the case where we were speaking of wishing to see a target of 90% of that activity being executed upon under the agreements we achieve in the program. We will report on that on an ongoing basis.
The next stage, of course, is the question of collaboration, where we have a particular objective to encourage spillovers through the program, so it's not simply a matter of R and D completely being conducted in-house inside the enterprise, but also in collaboration with our higher education institutes and research institutes so we have a transfer of knowledge, we have education of students, and we have a pathway for innovation to transfer across the two sectors. We will report on the extent of those collaborations over time.
Finally, we have a target in terms of 80% for those projects to lead to actual commercial outcomes, where the technology is transferred into a product that makes its way into the marketplace.
Of course, one doesn't do any of this with the assurance that all of it will turn out. It's all done in an environment where there's a risk being undertaken, that you ultimately achieve the objectives. But we have established targets in those areas and we will report on that publicly over time.